BIG news！SanReno Global Scientific Advisory Board Established

Shanghai, China -- January 10, 2023 SanReno announced the formal establishment of the Scientific Advisory Board (SAB). As a fast growing biotech company, SanReno is committed to providing innovative treatments and game-changing clinical solutions in nephrology and related therapeutic areas. The Global Scientific Advisory Committee will enhance SanReno’s understanding of science, guide innovative R&D activities, and ensure streamlined corporate strategy. 

James Huang, CEO of SanReno, said: "The establishment of SanReno Global Scientific Advisory Committee is an important milestone. We are pleased to invite world renowned experts in this industry to join in SanReno’s Global Scientific Advisory Committee and help us to fulfill our goals and strengthen our vision. Their deep understanding of science and rich experience in drug development are extremely valuable for the future success of our company. We believe that with their expertise, SanReno will be able to accelerate our breakthrough in the research and development of renal or other relevant therapeutic areas; offer safe, effective and innovative treatments for our patients, and create value for this society.  

SanReno SAB Members

 

Dr. Jonathan Barratt, Chairman of SanReno Global Scientific Advisory Committee

Dr. Jonathan Barratt is a world-renowned nephrologist, the Mayer Professor of renal medicine, Fellow of the Royal College of Physicians, Lead of Renal Research Group within the College of Life Sciences University of Leicester, as well as the head of the IgA nephropathy team of the National Registry of Rare Renal Diseases (RaDaR) in the UK and a member of the steering committee for the International IgA Nephropathy Network, Member of the Editorial Board of the International and Clinical Journal of Kidney, American Society of Nephrology. Dr. Barratt is also a member of the FDA and American Society of Nephrology Kidney Health Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgA Nephropathy Work group. Dr. Barratt has been focusing on the basic and clinical research of IgA nephropathy for many years and has carried out extensive cooperation with the pharmaceutical industry. He works closely with pharmaceutical companies interested in new treatments for IgA nephropathy and is Chief Investigator for a number of international randomized controlled Phase 2 and 3 clinical trials in IgA nephropathy.

Professor Minghui Zhao, member of SanReno Global Scientific Advisory Committee

Dr. Minghui Zhao is a world-renowned nephrologist, Professor & Chief Physician of Peking University, Director of Institute of Nephrology, Peking University as well as Executive Director of Asia Pacific Society of Nephrology, Chairman of Nephrology Committee of Chinese Preventive Medicine Association, Vice Chairman of Chinese society of Nephrology, President of Beijing Society of Immunology. Professor Minghui Zhao has been focusing on the pathogenesis of immune inflammation in kidney disease. He presided over the major programs of the National Natural Science Foundation of China and won the National Science Fund for Distinguished Young Scholars. Professor Minghui Zhao has won the China National Science and Technology Progress Award (twice), the Seville Award of the French National Academy of Medical Sciences, Wu Jieping-Paul Janssen Medical & Pharmaceutical Award, and the China Youth Science and Technology Award.

Dr. Zhengming Du, member of SanReno Global Scientific Advisory Committee

Dr. Zhengming Du has more than 30 years of chemistry and pharmaceutical industry experiences including research, development, registration, manufacturing and commercial. He has committed to the process optimization and performance qualifications, quality risk management and control of small molecule drugs, ensuring that the process and products meet China and global clinical and commercial requirements. He has published more than 30 academic papers in related fields and more than 20 international and domestic patents were authorized.  Dr. Zhengming Du used to be the senior vice president of BeiGene, head of CMC, the leading chemist of Novartis US, the deputy general manager of Zhejiang Huahai Pharmaceutical R&D Center, and the CMC director of Roche (China) Co., Ltd.  Dr. Du Zhengming has won the Global Resource Efficiency Award of Novartis, the Outstanding Contribution Award of Roche Innovation Project, the Outstanding Young Chemist Award of the Chinese Chemical Society, the Science and Technology Progress Award of Jiangsu Province, the leader of major scientific and technological innovation projects in Jiangsu Province, the leader of mass entrepreneurship and innovation teams in Jiangsu Province and other honors.